Superluminal Medicines closed an oversubscribed $60 million Series B to drive its next-gen obesity program and initiate the first clinical study. The company described a pipeline built around small-molecule GPCR-targeted therapies for endocrine and cardiometabolic diseases, supported by AI/machine learning, protein dynamics, and structural biology. The Series B provides runway for clinical execution and supports the translation from platform discovery into human safety, pharmacology, and dose exploration. For obesity, where competition is intense, the emphasis on next-generation GPCR targeting signals an attempt to differentiate beyond established GLP-1-centered approaches. From an industry perspective, the financing reinforces how investors continue to fund modality/platform transitions toward GPCR-drug discovery and first-in-human execution. It also highlights how clinical initiation remains the central milestone that turns platform stories into valuation anchors.